■骨髓抑制是化疗最常见的不良反应，严重影响治疗过程。足三里(ST36)穴位注射地塞米松在国内取得了较好的临床疗效。本研究旨在系统评价ST36穴位注射地塞米松治疗化疗所致骨髓抑制(CIM)的疗效。
■从8个电子数据库中检索ST36穴位注射地塞米松治疗CIM的随机对照试验。我们使用Cochrane协作工具来评估偏倚的风险。利用Excel2010建立信息提取数据库,采用RevMan5.3.0软件对纳入的试验数据进行分析。使用GRADEProfiler3.6软件对研究结果指标的证据质量进行评级。
■本荟萃分析共纳入17项研究，涉及1177名患者。结果表明,与常规西药(CWM)相比，ST36穴位注射地塞米松可显著提高临床总有效率[RR=1.95,95%CI(1.53,2.49),P<0.00001]和增加白细胞（WBC）（MD=1.38，95％CI（0.74，2.01），P<0.0001)和血红蛋白(Hb)水平[MD=3.89,95%CI(1.57,6.20),P=0.001]。此外,ST36穴位注射地塞米松可缩短骨髓抑制恢复时间[MD=-3.94,95%CI(-4.97~-2.91),P<0.00001]并改善Karnofsky绩效状态[MD=10.7，95%CI（1.36，20.05），P=0.02<0.05。然而,ST36穴位注射地塞米松和CWM在血小板（PLT）升高中没有显着差异[MD=4.61，95％CI（-10.14，19.35），P=0.54]。
■这项研究发现，ST36穴位注射地塞米松对CIM有积极作用。然而,更多设计良好的研究，大样本量，严格的随机化，未来需要对检测和报告过程进行明确的描述，以进一步确认ST36穴位注射地塞米松治疗CIM的疗效。
■https://www.crd.约克。AC.英国/,标识符CRD42021223979。
UNASSIGNED: Myelosuppression is the most common adverse reaction of chemotherapy, which seriously affects the course of treatment. Zusanli (ST36) acupoint injection with dexamethasone has achieved good clinical efficacy in China. This study aimed to systematically evaluate the efficacy of ST36 acupoint injection with dexamethasone in the treatment of chemotherapy-induced myelosuppression (CIM).
UNASSIGNED: Randomized controlled trials of CIM treated with ST36 acupoint injection with dexamethasone were retrieved from eight electronic databases. We used the Cochrane Collaboration tool to assess the risk of bias. Excel 2010 was used to establish a database for information extraction, and RevMan 5.3.0 software was used to analyze the included test data. GRADE profiler 3.6 software was used to grade the quality of evidence for the outcome indicators of the study.
UNASSIGNED: A total of 17 studies involving 1177 patients were included in this meta-analysis. The results showed that, compared with conventional western medicine (CWM), ST36 acupoint injection with dexamethasone could significantly improve the clinical total effective rate [RR=1.95, 95% CI (1.53, 2.49), P <0.00001] and increase white blood cell (WBC) (MD=1.38, 95% CI (0.74, 2.01), P<0.0001) and hemoglobin (Hb) levels [MD=3.89, 95% CI (1.57, 6.20), P=0.001]. In addition, ST36 acupoint injection with dexamethasone can shorten recovery time of myelosuppression [MD=-3.94, 95% CI (-4.97 to -2.91), P<0.00001] and improve Karnofsky performance status [MD=10.7, 95% CI (1.36, 20.05), P=0.02<0.05]. However, there was no significant difference among ST36 acupoint injection with dexamethasone and CWM in platelet (PLT) elevation [MD=4.61, 95% CI (-10.14, 19.35), P=0.54].
UNASSIGNED: This study found that ST36 acupoint injection with dexamethasone had a positive effect on CIM. However, more studies with well-designed, large sample size, strict randomization, and clear descriptions about detection and reporting processes are needed in the future to further confirm the efficacy of ST36 acupoint injection with dexamethasone in the treatment of CIM.
UNASSIGNED: https://www.crd.york.ac.uk/, identifier CRD42021223979.
PDF(Pubmed)